Retinal Function in Parkinson's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Edward Hines Jr. VA Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Edward Hines Jr. VA Hospital
ClinicalTrials.gov Identifier:
NCT01010074
First received: November 6, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted

November 6, 2009
November 6, 2009
October 2009
December 2010   (final data collection date for primary outcome measure)
pupillary threshold [ Time Frame: one ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Retinal Function in Parkinson's Disease
Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease

Parkinson's disease (PD) is a neurodegenerative disorder characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex arising from the basal ganglia normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high level cognitive dysfunction and subtle language problems. Included in the symptomatology experienced by patients with PD, visual abnormalities are not uncommon. Visual changes among patients with PD appear not only dynamic in nature, but differentially affected based on the course of the disease and, perhaps more importantly, its treatment. Parkinson's disease has significant ramifications not only in observation of irregularities in vision, but how vision interacts with entrainment of the circadian clock. The purpose of this study is to examine the relationship between PD and operation of a unique set of retinal cells known to regulate the circadian clock and sleep-wake cycles in human subjects.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

movement disorders/neurology clinic

Parkinson's Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria: age 18-64 best corrected visual acuity of 20/25 or better in each eye -

Exclusion Criteria: evidence of any form of eye disease, inability to understand and sign informed consent.

-

Both
18 Years to 64 Years
Yes
Contact: Bruce Ira Gaynes, OD, PharmD 708-216-6262 Bruce.Gaynes@va.gov
Contact: Jasvinder Chawla, MD 708-202-3800 Jasvinder.Chawla@va.gov
United States
 
NCT01010074
PD001
No
Bruce I. Gaynes, OD, PharmD, Hines VA Medical Center
Department of Veterans Affairs
Not Provided
Not Provided
Edward Hines Jr. VA Hospital
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP